ASCO 2024 | Genomic profiling of HR+/HER2- breast cancer and brain metastases

Gaia Griguolo • 5 Jun 2024

ASCO 2024

Breast Cancer

Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses findings from the genomic profiling study of paired primary breast cancer and brain metastases. Key findings include increased expression of HER2-enriched and luminal B subtypes in brain metastases, and upregulation of genes were associated with survival, proliferation, and migration. These results highlight the biological complexity of brain metastases and suggest potential therapeutic targets. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Gilead Sciences; Menarini; Seagen
Speakers’ Bureau – Lilly; MSD
Travel, Accommodations, Expenses – Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer